The per-protocol effect of immediate versus deferred antiretroviral therapy initiation

AIDS

Volumn 30, Issue 17, 2016, Pages 2659-2663

  Lodi, Sara ^a   Sharma, Shweta ^b   Lundgren, Jens D ^c   Phillips, Andrew N ^d   Cole, Stephen R ^e   Logan, Roger ^a   Agan, Brian K ^f,g   Babiker, Abdel ^d   Klinker, Hartwig ^h   Chu, Haitao ^b   Law, Matthew ⁱ   Neaton, James D ^b   Hernán, Miguel A ^a,j  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e IL   (United States)

^f UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^g HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^h UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

ⁱ UNIVERSITY OF NEW SOUTH WALES   (Australia)

^j HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

more..

Author keywords

Antiretroviral treatment; G formula; HIV; Per protocol effect

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT;

ADULT; ANTIRETROVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL OUTCOME; CLINICAL PROTOCOL; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; MALE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TIME FACTOR; TREATMENT OUTCOME;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84986238270     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000001243     Document Type: Article

References (9)

1. Insight Start Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015; 373: 795-807.
2. Hernan MA, Hernandez-Diaz S. Beyond the intention-to-treat in comparative effectiveness research. Clin Trials 2012; 9: 48-55.
3. Department of Health and Human Services (DHHS). Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.Department of Health and Human Services (DHHS); 2015.
4. European AIDS Clinical Society (EACS). European guidelines for treatment of HIV infected adults in Europe.2015.
5. World Health Organization (WHO). Guideline on when to start antiretroviral therapy and on preexposure prophylaxis for HIV. Switzerland: World Health Organization (WHO); 2015.
6. Robins J, Hernan M. Estimation of the causal effects of timevarying exposures. In: Fitzmaurice GD, Davidian M, Verbeke M, Molenberghs G,editors. Advances in longitudinal data analysis. Boca Raton, Florida: Chapman and Hall/CRC Press; 2009. pp. 553-599.
7. Robins JM. A new approach to causal inference in mortality studies with a sustained exposure period: Application to the healthy worker survivor effect. Math Model 1986; 7: 1393-1512.
8. Young JG, Cain LE, Robins JM, O'Reilly EJ, Hernan MA. Comparative effectiveness of dynamic treatment regimes: An application of the parametric g-formula. Stat Biosci 2011; 3: 119-143.
9. Murray EJ, Hernan MA. Adherence adjustment in the Coronary Drug Project: A call for better per-protocol effect estimates in randomized trials. Clin Trials 2016; 13: 372-378.